This study also identified a subgroup of patients with the toll-interacting protein (TOLLIP) TT genotype in which NAC monotherapy was associated with a significant decrease in the composite endpoint of lung disease progression, hospital admission, transplantation, or death (hazard ratio 0.14). This evidence concerns the gene TOLLIP and lung disorder.